89.55
전일 마감가:
$91.99
열려 있는:
$90.3
하루 거래량:
1.17M
Relative Volume:
1.06
시가총액:
$22.65B
수익:
$3.26B
순이익/손실:
$-1.45B
주가수익비율:
-15.25
EPS:
-5.871
순현금흐름:
$1.18B
1주 성능:
-4.86%
1개월 성능:
-9.97%
6개월 성능:
-13.13%
1년 성능:
-3.02%
바이오앤테크 Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
BNTX
Biontech Se Adr
|
89.55 | 23.26B | 3.26B | -1.45B | 1.18B | -5.871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM - Yahoo Finance
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? - TradingView
BNTX Stock Quote Price and Forecast - CNN
BioNTech authorizes $1 billion share buyback program By Investing.com - Investing.com South Africa
BioNTech authorizes $1 billion share buyback program - Investing.com
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides - Barchart.com
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year - Morningstar
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - sharewise.com
BioNTech Q1 Earnings Call Highlights - Yahoo Finance
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides - ChartMill
BioNTech earnings ahead: Can oncology offset plunging vaccine sales? - Investing.com
Mitsubishi UFJ Trust & Banking Corp Sells 92,271 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s Cancer Pivot Faces a Defining Week as Founders Head for the Door () - aktiencheck.de
SanDisk, Western Digital, Clorox And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
BioNTech (NASDAQ:BNTX) Shares Gap DownWhat's Next? - MarketBeat
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE - MarketBeat
Tangible book value per share of BioNTech SE Sponsored ADR – XETR:22UA - TradingView
BioNTech's $5.5 Million Insider Sale Precedes a Pivotal May for the Biotech () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE (MEX:BNTXN) Stock Price, Trades & News - GuruFocus
Sierk Poetting Sells 50,000 Shares of BioNTech (NASDAQ:BNTX) Stock - MarketBeat
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BioNTech's Oncology Ambitions Hinge on Landmark Data and Shareholder Vote () - aktiencheck.de
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
BioNTech's Pancreatic Cancer Vaccine Shows Unprecedented Long-Term Survival () - aktiencheck.de
BioNTech's Oncology Pipeline Delivers Critical Data as Strategic Pivot Accelerates () - aktiencheck.de
BNTX Earnings History & Surprises | EPS & Revenue Results | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch - TipRanks
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Impfung: Between Pandemic Legacy and Oncology Pivot, Future Hinges on Pipeline Wins - AD HOC NEWS
BioNTech's Shareholder Vote Puts Dilution in Focus Amid Oncology Advance () - aktiencheck.de
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baillie Gifford & Co. - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (IDYA), BioNTech SE (BNTX) and Stryker (SYK) - The Globe and Mail
BioNTech's Cancer Drug Data Fuels Optimism Amid Financial Headwinds () - aktiencheck.de
Net income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID - TipRanks
BioNTech's $17 Billion War Chest Fuels High-Stakes Oncology Pivot () - aktiencheck.de
Operating income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech's Shareholder Vote to Cement Post-Pandemic Strategy () - aktiencheck.de
Why Is Pfizer Stock Dropping Tuesday? - Sahm
European ADRs Slipped As Biotech Lagged And UK Names Rose - Finimize
BioNTech Shifts Strategy with Dual Operational Pullbacks () - aktiencheck.de
BioNTech's Strategic Pivot: Fueling Oncology Ambition with Capital Reserves () - aktiencheck.de
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):